Every 8-K that Generation Bio Co. (GBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GBIO filings page.
Generation Bio Co. has been acquired by XOMA Royalty Corporation. Parent’s tender offer closed with 4,722,533 shares, about 70% of the common stock, validly tendered. Each share is being exchanged for $4.2913 in cash plus one non-tradeable contingent value right (CVR).
Following the tender, a short-form merger under Delaware law made Generation Bio a wholly owned subsidiary of XOMA, and all remaining shares were converted into the same cash-and-CVR consideration. The company has requested delisting from Nasdaq and plans to terminate its SEC reporting obligations.
In connection with the takeover, all prior directors resigned and Owen Hughes became sole director and officer. The company terminated its ATM equity program and all stock incentive and purchase plans. It also agreed to pay about $21.5 million to terminate its headquarters lease, while the landlord will return a roughly $2 million letter of credit.
Generation Bio Co. entered into a definitive agreement to be acquired by XOMA Royalty Corporation through a tender offer. Stockholders will be offered $4.2913 in cash plus one contingent value right (CVR) for each share of common stock, with the CVR providing potential future cash payments under a separate CVR agreement.
After the tender offer, a follow-on merger under Delaware law is expected to make Generation Bio a wholly owned subsidiary of XOMA Royalty, with closing anticipated in or around February 2026, subject to customary conditions including more than 50% of shares being tendered. Support agreements have been signed by holders of about 15.38% of the shares, and the board unanimously approved the transaction and recommends that stockholders tender into the offer. The merger agreement includes a termination fee of $840,000 payable by Generation Bio in certain circumstances.
Generation Bio Co. filed a current report to let investors know it has released its latest quarterly financial results. The company issued a press release covering its results for the quarter ended September 30, 2025, and attached that release as an exhibit to this report.
The press release is furnished, not filed, which means it is provided for information but is not automatically subject to certain legal liabilities or incorporated into other regulatory documents unless specifically referenced. The report is signed by Yalonda Howze, the company’s Interim Chief Executive Officer and President.
Generation Bio Co. announced leadership changes. Geoff McDonough, M.D. will resign as Chief Executive Officer effective October 31, 2025, and will become chairman of the Board. Under a separation agreement, he will receive cash severance of approximately $700,000, a payment in lieu of bonus of approximately $300,000 for 2025, up to 12 months of healthcare coverage, and 25% acceleration of his outstanding unvested equity awards. He will also receive a $70,000 bonus related to the company’s strategic alternatives review.
The company plans to engage Dr. McDonough as a consultant through October 31, 2026 at $500 per hour, with continued equity vesting during consulting. The Board elected Yalonda Howze as Interim CEO and President, with a $575,000 base salary and a target bonus set at 50% of base, plus specified severance protections, including enhanced benefits upon a change in control. Consulting agreements are also expected with COO Antoinette Paone ($360/hour) and CSO Phillip Samayoa ($400/hour) through October 31, 2026, with continued equity vesting.
Generation Bio Co. furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is being furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The Form 8-K itself does not include any financial figures, metrics, or narrative of the results; readers must consult Exhibit 99.1 for the actual numbers and commentary.